AADC deficiency from infancy to adulthood: Symptoms and developmental outcome in an international cohort of 63 patients.
Adolescent
Adult
Age Factors
Amino Acid Metabolism, Inborn Errors
/ physiopathology
Aromatic-L-Amino-Acid Decarboxylases
/ deficiency
Child
Child, Preschool
Dopamine Agonists
/ adverse effects
Dystonic Disorders
/ etiology
Female
Genetic Therapy
Humans
Infant
Internationality
Male
Ocular Motility Disorders
/ etiology
Phenotype
Retrospective Studies
Young Adult
dystonia-parkinsonism
gene therapy
natural history
neurotransmitter disorders
rare diseases
Journal
Journal of inherited metabolic disease
ISSN: 1573-2665
Titre abrégé: J Inherit Metab Dis
Pays: United States
ID NLM: 7910918
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
10
03
2020
revised:
10
04
2020
accepted:
27
04
2020
pubmed:
6
5
2020
medline:
6
10
2021
entrez:
6
5
2020
Statut:
ppublish
Résumé
Aromatic l-amino acid decarboxylase deficiency (AADCD) is a rare, autosomal recessive neurodevelopmental disorder characterized by impaired synthesis of dopamine, noradrenaline, adrenaline and serotonin, leading to a complex syndrome of motor, behavioral, and autonomic symptoms. This retrospective study assessed the symptoms and developmental outcome of a large international cohort of patients with AADCD via physician and/or caregiver responses to a detailed, standardized questionnaire. Sixty-three patients (60% female; ages 6 months-36 years, median 7 years; 58 living) from 23 individual countries participated. Common symptoms at onset (median age 3 months, range 0-12 months) were hypotonia, developmental delay, and/or oculogyric crises. Oculogyric crises were present in 97% of patients aged 2 to 12 years, occurred in the majority of patients in all age groups, and tended to be most severe during early childhood. Prominent non-motor symptoms were sleep disturbance, irritable mood, and feeding difficulties. The majority of subjects (70%) had profound motor impairment characterized by absent head control and minimal voluntary movement, while 17% had mild motor impairment and were able to walk independently. Dopamine agonists were the medications most likely to produce some symptomatic benefit, but were associated with dose-limiting side effects (dyskinesia, insomnia, irritability, vomiting) that led to discontinuation 25% of the time. The age distribution of our cohort (70% of subjects under age 13 years) and the observation of a greater proportion of patients with a more severe disease phenotype in the younger compared to the older patients, both suggest a significant mortality risk during childhood for patients with severe disease.
Identifiants
pubmed: 32369189
doi: 10.1002/jimd.12247
pmc: PMC7540529
doi:
Substances chimiques
Dopamine Agonists
0
Aromatic-L-Amino-Acid Decarboxylases
EC 4.1.1.28
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1121-1130Subventions
Organisme : NINDS NIH HHS
ID : R01 NS094292
Pays : United States
Organisme : Department of Health
ID : RP-2016-07-019
Pays : United Kingdom
Informations de copyright
© 2020 The Authors. Journal of Inherited Metabolic Disease published by John Wiley & Sons Ltd on behalf of SSIEM.
Références
Lancet Child Adolesc Health. 2017 Dec;1(4):265-273
pubmed: 30169182
Sci Transl Med. 2012 May 16;4(134):134ra61
pubmed: 22593174
JIMD Rep. 2018;40:1-6
pubmed: 28856607
J Inherit Metab Dis. 2009 Jun;32(3):371-80
pubmed: 19172410
Mol Genet Metab. 2019 May;127(1):12-22
pubmed: 30952622
J Inherit Metab Dis. 1990;13(3):301-4
pubmed: 1700191
Eur J Paediatr Neurol. 2009 Mar;13(2):135-40
pubmed: 18567514
J Inherit Metab Dis. 2020 May;43(3):602-610
pubmed: 31849064
J Inherit Metab Dis. 2020 Sep;43(5):1121-1130
pubmed: 32369189
Mol Genet Genomic Med. 2020 Mar;8(3):e1143
pubmed: 31975548
JIMD Rep. 2015;15:39-45
pubmed: 24788355
Brain Dev. 2010 Jun;32(6):506-10
pubmed: 19520530
Brain. 2019 Feb 1;142(2):322-333
pubmed: 30689738
Mol Genet Metab Rep. 2016 Oct 20;9:61-66
pubmed: 27830117
Orphanet J Rare Dis. 2017 Jan 18;12(1):12
pubmed: 28100251
Neurology. 2004 Apr 13;62(7):1058-65
pubmed: 15079002
Mov Disord Clin Pract. 2018 May 12;5(4):446-447
pubmed: 30838302
Neurology. 2010 Jul 6;75(1):64-71
pubmed: 20505134
Mol Genet Metab. 2007 Aug;91(4):374-8
pubmed: 17533144